Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
Rhea-AI Summary
NanoViricides (NYSE American: NNVC) highlights NV-387, a broad-spectrum antiviral, as a potential oral treatment for the Bundibugyo Ebola outbreak in eastern DRC and Uganda. NV-387 is designed to mimic sulfated proteoglycans used by filoviruses for cell attachment.
The drug is room‑temperature stable, formulated as oral gummies, and is being advanced toward Phase II clinical trials for respiratory and poxvirus infections. NanoViricides holds broad exclusive licenses for antiviral nanomedicine technology from TheraCour and is developing candidates against multiple serious viral diseases.
Positive
- NV-387 positioned as broad-spectrum antiviral targeting multiple filoviruses, including Ebola
- Oral, room-temperature-stable NV-387 gummies may simplify use in remote outbreak settings
- Company is advancing NV-387 toward Phase II human clinical trials
- Pipeline includes additional candidate NV-HHV-1 for Shingles treatment
- NanoViricides holds broad, exclusive, sub-licensable licenses for numerous viral disease targets
Negative
- Company cannot project exact IND filing dates due to external dependencies
- Drug development path described as extremely lengthy and requiring substantial capital
- No assurance NV-387 or other candidates will show sufficient safety and effectiveness
- Laboratory success against viruses may not translate into successful clinical trials or products
News Market Reaction – NNVC
In the May 18 session, NNVC gained 2.03%, reflecting a moderate positive market reaction. Argus tracked a peak move of +21.4% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Registered offering | Negative | -14.9% | Dilutive ~$2M registered direct offering with warrants at $1.75. |
| May 15 | 10-Q and pipeline | Negative | -14.9% | 10-Q showing NV-387 progress but funding insufficient for all programs. |
| May 11 | Disease risk promo | Positive | -3.9% | NV-387 promoted as broad-spectrum answer to cruise-ship hantavirus. |
| May 06 | Conference participation | Neutral | +0.0% | Investor conference appearance and one-on-one meetings in New York. |
| May 04 | Orphan designation | Positive | +15.4% | FDA Orphan Drug Designation for NV-387 in Measles with Phase II plans. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often led to price moves aligned with the underlying tone: positive regulatory milestones saw gains, while financings and going-concern risks coincided with declines.
Over the last weeks, NanoViricides highlighted NV-387’s broad-spectrum potential and advanced it toward Phase II, including Measles Orphan Drug Designation on May 4, 2026 with a 15.38% price gain. Subsequent promotional and conference news had modest to flat impact. On May 15, 2026, a registered direct offering of about $2 million and a 10-Q noting limited funding runway both coincided with a 14.94% decline. Today’s Ebola-focused NV-387 positioning fits the pattern of using emerging outbreaks to underscore the same lead asset.
Key Terms
ebolavirus medical
filoviruses medical
sulfated proteoglycans medical
orphan drug designation regulatory
phase ii medical
public health emergency of international concern (pheic) regulatory
case fatality rate (cfr) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the critical need for a revolutionary, broad-spectrum, antiviral drug like NV-387 as another severe Ebolavirus outbreak has occurred in the Eastern part of DR Congo (DRC), with spillage across the border into Uganda.
"We believe NV-387 could be effective against the Bundibugyo strain of Ebola that is ravaging DRC," said Anil R. Diwan, PhD, adding, "All filoviruses including all Ebola strains utilize the sulfated proteoglycans for initial cell attachment; which is the feature that NV-387 presents to the viruses to destroy them."
Viruses are unlikely to escape NV-387 because no matter how much the viruses change, they still depend upon their interaction with sulfated proteoglycans for initial attachment to cells, which NV-387 mimics.
In contrast, antibodies and vaccines are highly specific, and are readily escaped by viruses. Further, antibodies require a cold chain and must be given as infusions in patients. The equipment and facilities for the cold chain and for infusion itself in a high isolation setting are generally not available in remote areas.
NV-387 is an oral medication that has excellent stability at room temperature, enabling ease of transport, distribution, and delivery to patient. NV-387 oral gummies dissolve naturally in the mouth and do not require tablet swallowing, which is difficult for children, seniors, and also patients with sore throat.
If NV-387, as a broad-spectrum antiviral, is found to be effective against the Bundibugyo virus, it will likely be effective against all ebolaviruses or all filoviruses; that would be a game changer for pandemic preparedness.
Currently there is no treatment or vaccine for the Bundibugyo virus. All previous efforts have been focused on vaccines and antibodies[1]. This has led to approval of therapies that are specific to the Zaire strain only, albeit with limited effectiveness. This leaves out all other filoviruses of consequence: Sudan, Marburg, and the more rare Bundibugyo with no treatment or vaccine.
The WHO declared a Public Health Emergency of International Concern (PHEIC) for the Bundibugyo outbreak in Eastern DRC, with two cases in Uganda in travelers from Congo, on May 17, 2026[2]. The outbreak itself was declared on May 15, although the initial or "patient zero" case likely occurred in April, 2026. This delay was primarily because of the cases occurring in clusters in multiple remote locations that had limited reporting capabilities. The outbreak had already resulted in 88 deaths and at least 336 suspected cases[3]. WHO estimates there could be potentially a much larger outbreak with many unreported or undiagnosed cases.
Some Americans currently in DRC have been affected. It is not clear if they have been traced as contacts, or have acquired infection awaiting diagnosis. The US CDC with other US departments is active in extracting these subjects exposed to ebolavirus and moving them into an isolated area for treatment, if necessary.[4]
The case fatality rate of ebolaviruses has generally been around
An irony is that because of the high case fatality rate (CFR) approaching
With ever-increasing global travel, local outbreaks such as ebola can quickly travel far and wide potentially causing global pandemics, as was the case with COVID-19, if not caught in time. It is not feasible to produce a new vaccine and a new set of antibody drugs to combat every possible virus. Even if vaccines and antibodies are produced, the virus would escape by generating variants, as the world has witnessed during the COVID-19 pandemic.
"Only safe and effective broad-spectrum antiviral drugs that can effectively combat most viral infections will enable the world to combat viruses and defend the global population in the war against known and unknown nanoscopic enemies that are viruses," commented Dr. Diwan, adding, "NV-387 is the only drug with such potential that is in clinical development today, to the best of our knowledge."
NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.
Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
[1] Substantial work was also performed to develop small chemical potentially broad-spectrum agents. Remdesivir was the only small chemical that entered the PALM clinical trials ca. 2018-2019 but failed to show effectiveness. Small chemicals are readily escaped by viruses often with just single mutations.
[4] https://www.statnews.com/2026/05/17/ebola-outbreak-congo-americans-exposure-suspected-cases/
SOURCE: NanoViricides
View the original press release on ACCESS Newswire